Articles > Popular publications > PR Newswire press releases > October-December 2003 > Friday, December 5

Article: FDA Approves Risperdal (R) for Treatment of Bipolar Mania.

Article from:
PR Newswire
Article date:
December 5, 2003
Copyright

The U.S. Food and Drug Administration (FDA) has approved RISPERDAL (R) (risperidone) as monotherapy (alone) or in combination with lithium or valproate for the short-term treatment of acute manic or mixed episodes associated with bipolar I disorder, also known as bipolar mania. In research studies, patients with bipolar mania who took Risperdal showed significant improvement in manic symptoms compared to placebo.

Bipolar disorder affects more than 2 million people in the United States and is characterized by dramatic mood swings, alternating between the highs of mania and the lows of depression. In mixed episodes, people with bipolar disorder experience ... 







Read all of this article with a FREE trial
















Related newspaper, magazine, and journal articles:









  




 

    

 
 
   
 


   
  
  Article: Risperdal (R) Consta (R), First and Only Long-Acting, ...

  
  PR Newswire; 
  December 3, 2003 ;  
  
  
 
  700+ words
... ... as many as 75 percent of patients with ... regular basis. "Risperdal Consta offers physicians ... clinical trials, Risperdal Consta was generally ... an incidence of 5 percent or greater in at least one of the Risperdal Consta groups ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: RISPERDAL(R) (RISPERIDONE) ORAL FORMULATION NEW OPTION FOR ...

  
  PR Newswire; 
  July 15, 1996 ;  
  
  
 
  700+ words
... ... its ease of administration, Risperdal oral solution will provide ... treatment with medication. Risperdal oral solution will be an effective ... Research Corporation, 50 percent of health care professionals ... tablets to ease administration. Risperdal oral solution eliminates the ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: RISPERDAL (R) (risperidone) Shown to Rapidly Reduce Manic ...

  
  PR Newswire; 
  June 2, 2004 ;  
  
  
 
  700+ words
... ... more patients treated with Risperdal (43 percent) compared to those taking ... significantly more patients taking Risperdal (38 percent) compared to those taking ... both treatment groups (8 percent of Risperdal patients compared to 6 percent ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: RISPERDAL[R] CONSTA[R] Approved in Japan.

  
  Business Wire; 
  April 27, 2009 ;  
  
  
 
  700+ words
... ... Devices Agency (PMDA) in Japan to market RISPERDAL([R]) CONSTA([R]) [(risperidone ... for the treatment of schizophrenia. RISPERDAL CONSTA is the first long-acting atypical ... Drug Price Standard. "The approval of RISPERDAL CONSTA in Japan represents another important ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: Risperdal reduces acute bipolar mania symptoms as early as ...

  
  Biotech Week; 
  June 30, 2004 ;  
  
  
 
  700+ words
... ... scale, clinical trial show that when Risperdal (risperidone) was used to treat patients ... patients in the 3-week study receiving Risperdal achieved significantly higher rates of ... four patients were randomized to the Risperdal monotherapy group and 125 to the placebo ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: FDA Approves RISPERDAL(R) to Treat Adolescents with ...

  
  PR Newswire; 
  August 22, 2007 ;  
  
  
 
  700+ words
... ... Administration (FDA) today approved RISPERDAL(R) (risperidone) for the treatment ... mixed episodes of bipolar I disorder. RISPERDAL is marketed in the U.S. by Janssen ... mental health. For more information about RISPERDAL, visit http://www.janssen.com ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: JANSSEN'S RISPERDAL SURPASSES CONVENTIONAL THERAPIES AS ...

  
  Business Wire; 
  October 1, 1996 ;  
  
  
 
  700+ words
... ... capturing 20.7 percent of the market ... prescriptions written for Risperdal surpassed those ... prescriptions for Risperdal increased by 80 percent, while prescriptions ... increased only six percent. Since its introduction, Risperdal has become a standard ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: FDA approves Risperdal as monotherapy or in combination ...

  
  Pain & Central Nervous System Week; 
  December 29, 2003 ;  
  
  
 
  700+ words
... ... Participants taking Risperdal, on average, experienced ... patients. Forty-three percent of the patients treated with Risperdal versus 24% of the patients ... patients. Fifty-seven percent of patients treated with Risperdal versus 38% of patients ... 







   
 

























 



 





 






Newsweek
Harper's Magazine
The Washington Post
Chicago Tribune
Crain's Chicago Business
PRNewswire
Pediatric News
The Nation
Advertising Age
The Economist (US)
A FREE trial gives you access to over 80 million articles!
Access over 6,500 publications with a FREE trial!


  



Find articles, research, and archives